What's the problem?
For a long time, paediatric medicine development has largely been neglected, meaning that drugs used in children have not been appropriately tested in paediatric populations. However, European legislation introduced more than 10 years ago, as well as equivalent legislation in the United States, have stimulated research efforts in this area. Yet despite these developments, there are still many challenges and unmet medical needs to address, including childhood cancer; a fraction of the number of anti-cancer medicines for kids are authorised compared to those for adults, for example.
What is IMI doing about it?
We're setting up a sustainable infrastructure for delivering paediatric clinical trials, transforming the way clinical trials are conducted particularly for paediatric rare diseases, building a platform to identify promising molecules to fight paediatric cancer, studying genetic newborn screening for rare diseases, and tackling infectious diseases that plague children, all while placing kids and their families at the centre of research.
IMI research is...
|...addressing childhood cancer||
|... building clinical trial networks and improving on their design||
|...identifying biomarkers and driving personalised medicine||
|…tackling infectious diseases in children||
|... studying the safety of medications during pregnancy and breastfeeding||
|...putting parents and children at the centre of research||